Ziopharm Oncology Responds to Recent Stock Decline and Clarifies Exclusivity Rights for Clinical Assets

12:06 EST 28 Dec 2018 | Investing News Network

Ziopharm Oncology (Nasdaq:ZIOP) today responded to the recent decline in the Company’s stock price, which accelerated greatly on December 26, 2018, the same day that the broader market and all indexes were up significantly. As quoted in the press release: “Our stock price is significantly down of late, and we want to assure the market … Continued

More From BioPortfolio on "Ziopharm Oncology Responds to Recent Stock Decline and Clarifies Exclusivity Rights for Clinical Assets"